托珠单抗(Tocilizumab) - 药物靶点：IL-6RA_在研适应症：系统性硬化相关的间质性肺病，成人斯蒂尔病，大动脉炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Atlizumab、MRA-SC、Tocilizumab (Genetical Recombination)

+ [14]

靶点

IL-6RA

作用方式

拮抗剂

作用机制

IL-6RA拮抗剂(白细胞介素-6受体α亚基拮抗剂)

治疗领域

免疫系统疾病感染神经系统疾病+ [7]

在研适应症

系统性硬化相关的间质性肺病成人斯蒂尔病大动脉炎+ [18]

非在研适应症

肌萎缩侧索硬化贫血强直性脊柱炎+ [21]

原研机构

Chugai Pharmaceutical Co., Ltd.

在研机构

Hoffmann-La Roche, Inc.Roche Registration GmbH

Chugai Pharmaceutical Co., Ltd.

+ [7]

非在研机构

F. Hoffmann-La Roche Ltd.Roche Pharma AG

Gilead Sciences, Inc.

+ [1]

权益机构

Hoffmann-La Roche Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2005-04-11),

Castleman病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、紧急使用授权 (美国)、孤儿药 (美国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 12264H

来源: *****

Sequence Code 12270L

来源: *****

关联

598

项与托珠单抗相关的临床试验

NCT06381661

/ Not yet recruiting临床3期IIT

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

开始日期2026-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT03787290

/ Suspended临床2期IIT

Examining Immune-Based Mechanisms of Action for Mild-Intensity Whole Body Hyperthermia (WBH) in the Treatment of Major Depressive Disorder

Overall, the objective of this pilot study is to utilize the IL-6 receptor antagonist tocilizumab to prospectively evaluate the role of IL-6 in the antidepressant and immunological effects of whole body hyperthermia (WBH). The study seeks to replicate findings thus far that WBH has an antidepressant effect by administering the intervention at a site not involved in studies to date. Moreover, the current proposal may help the investigators better understand the role of IL-6 in the pathogenesis and treatment of depression which might point to novel immune-based interventions for Major Depressive Disorder (MDD). Finally, the current proposal holds promise for better understanding of a novel treatment for MDD, which is among the leading causes of health-related disability in the world.

开始日期2025-12-01

申办/合作机构

The General Hospital Corp.

[+1]

NCT06654882

/ Not yet recruiting临床3期IIT

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

开始日期2025-08-01

申办/合作机构

Duke University

[+1]

100 项与托珠单抗相关的临床结果

登录后查看更多信息

100 项与托珠单抗相关的转化医学

登录后查看更多信息

100 项与托珠单抗相关的专利（医药）

登录后查看更多信息

7,155

项与托珠单抗相关的文献（医药）

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Amyloidosis in Human Inborn Errors of Immunity Predicts Poor Prognosis

Article

作者: Silleli, Onat ; Çağdaş, Deniz ; Esenboğa, Saliha ; Samur, İncinur ; Aytekin, Elif Soyak ; Sağlam, Emine Arzu ; Demirel, Fevzi ; Tagiyev, Anar

Abstract:

Purpose:

Chronic inflammation in inborn errors of immunity(IEI) caused by the infections or immune dysregulation is associated with the amyloid A (AA) amyloidosis development. This study aims to analyze the clinical characteristics, management strategies, and outcomes of patients with IEI complicated by AA amyloidosis, focusing on demographics, disease manifestations, treatment modalities, and survival rates.

Methods:

Thirteen patients diagnosed with IEI and AA amyloidosis, along with an additional 10 patients previously reported from Türkiye, were reviewed retrospectively.

Results:

The median ages at diagnosis of IEI and amyloidosis were 20 years (2–61) and 25 years (7–70), respectively. Renal (74%) and gastrointestinal involvement (44%) were the most common, followed by skin(9%), pulmonary (9%), and cardiac involvement (9%). Primary antibody deficiencies(48%), combined immunodeficiencies(31%), hyperimmunoglobulin E syndrome(9%), congenital neutropenia (4%), autoinflammatory disorders (4%), and chronic mucocutaneous candidiasis (4%) were the IEI types associated with amyloidosis. Bronchiectasis (74%) and malignancy (17%) were observed in given ratio of patients. Treatment modalities for amyloidosis include colchicine (n = 12, 52%), steroids (n = 5, 22%) and tocilizumab (n = 2, 9%) without significant benefit. Thirteen patients (57%) died with a median age of 24 years (8–45), predominantly due to sepsis (52%). Familial Mediterranean fever (FMF) gene analysis was negative in all patients except for one, who had a heterozygous MEFV gene defect (M694V).

Conclusion:

AA amyloidosis in IEI is associated with severe morbidity and mortality. Early diagnosis and management of IEI are crucial to prevent amyloidosis development. However, colchicine appears ineffective once amyloidosis has occurred, highlighting the need for further research into early diagnostic biomarkers and novel treatment options.

2025-12-01·INFLAMMATION RESEARCH

COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th2 cytokines in a systemic mastocytosis patient

Article

作者: Gowran, Aoife ; Jilma, Bernd ; Brankovic, Jelena ; Weiss-Tessbach, Matthias ; Mühlbacher, Jakob ; Schubert, Lorenz ; Boehm, Thomas ; Wahrmann, Markus ; Haider, Teresa

Abstract:

Objective and design:

SARS-CoV-2 vaccines are recommended for mastocytosis patients. We describe clinical symptoms, chemokine, cytokine, metabolomic and lipidomic derangements in a systemic mastocytosis patient following mRNA-1273 booster vaccination.

Methods:

Twenty-eight chemokines and cytokines, 41 amino acids and 16 lipid classes were quantified with state-of-the-art methods.

Results:

Mast cell activation (MCA) symptoms started 24 h after the mRNA-1273 booster vaccination with significant metabolic, lipidomic and cytokine derangements. Histamine concentrations peaked at life-threatening 18 ng/ml concomitant with high tryptase. Peak plasma IL-1Ra, IL-5, IL-6, IL-10, IL-11, CXCL10 and GM-CSF concentrations were elevated 54-, 4.9-, 85-, 54-, 6.1-, 19- and 6.4-fold respectively. Tocilizumab, an IL-6 receptor antagonist, was administered 6 h after admission, because of the highly elevated IL-6 concentrations. More than one year later IL-6 was highly elevated during another MCA attack likely caused by a PCR-proven SARS-CoV-2 infection and tocilizumab was again used. Clinical symptoms improved during the following 12 h similar to the vaccine booster MCA attack.

Conclusions:

A mRNA-1273 first booster vaccination likely caused a delayed severe MCA attack with highly elevated Th2-biased cytokines with metabolic and lipidomic derangements. Administration of an IL-6 receptor blocker during both MCA attacks might have shortened the duration of clinical symptoms.

2025-10-01·JOINT BONE SPINE

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

Article

作者: Hoang, Sylvie ; Gottenberg, Jacques-Eric ; Lukas, Cédric ; Soubrier, Martin ; Mariette, Xavier ; Wendling, Daniel ; Roth, Olivier ; Goupille, Philippe ; Briançon, Daniel ; Wetzman, Amélie ; Morel, Jacques

OBJECTIVE:

Our study aimed to estimate the incidence and risk factors of cancer among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and followed for five years in the French registry (REGATE).

METHOD:

The REGATE registry is a French prospective cohort study investigating the safety of TCZ in RA (registration n^o: 910346). Data were collected using an e-CRF between 2011 and 2016 and with a questionnaire specifically distributed to participating centers that reported malignancies in REGATE. We mainly focused on solid cancers, hematological malignancies, and non-melanoma skin cancers (NMSC). To identify potential risk factors associated with cancer, we performed a univariate analysis and a multivariate analysis using Cox proportional hazards models.

RESULTS:

Our study included 1496 patients with RA who were treated with TCZ for a mean duration of 32.0 (±22.0) months and followed for an average of 47 (±15.2) months, resulting in a total exposure of 3990.9 patient-years (PY). Of these patients, 63 (4.2%) were diagnosed with a total of 75 cancers during the follow-up period (35 solid neoplasms, 11 hematological malignancies, 3 melanomas, and 26 NMSC). The overall incidence of cancer excluding NMSC was 7.5/1000 PY (exposure time). Our multivariate analysis revealed that high age (HR=1.05 [1.02-1.08]), current smoker (HR=2.65 [1.27-5.53]) and male 2.38 [1,18-4,80]) were independent risk factors for solid cancers. Age and active smoking were associated with higher risk of hematological malignancies.

CONCLUSION:

We found no additional risk factors of cancer for RA patients under TCZ, beyond those already known in the general population.

524

项与托珠单抗相关的新闻（医药）

2025-06-30

·GBIHealth

晶泰科技与辉瑞扩大合作，共同开发全新一代的分子模拟平台

药械追踪No.1 / 辉瑞抗菌药思福诺获国家药监局批准上市2025年6月30日，辉瑞公司今日宣布，新型抗菌药物思福诺（注射用氨曲南阿维巴坦钠）获得国家药品监督管理局正式批准，用于治疗由革兰阴性菌引起的治疗药物选择有限或无替代治疗的成人复杂性腹腔内感染（cIAI），医院获得性肺炎（HAP），包括呼吸机相关性肺炎（VAP）。思福诺是首个能够覆盖CRE全酶型的β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂，通过固定复方设计，思福诺不仅能够覆盖KPC及OXA-48碳青霉烯酶，还有效针对产MBL的细菌，克服了既往β-内酰胺酶抑制剂复方制剂不能覆盖MBL的问题。其具有广谱抑酶活性，在改善患者治疗结局的同时降低耐药发生风险。->点击文末阅读原文，解锁完整双语新闻No.2 / 吉利德一年给药两次HIV预防药物来那帕韦获博鳌乐城批准2025年6月30日，吉利德宣布，HIV暴露前预防（PrEP）药物来那帕韦（lenacapavir）已获海南博鳌乐城国际医疗旅游先行区批准，用于有感染HIV-1风险的成人和体重不小于35公斤的青少年进行暴露前预防，以降低通过性行为感染HIV-1的风险。来那帕韦旨在抑制HIV生命周期的多个阶段，在III期PURPOSE 系列研究中展现出显著预防效力。2025年6月18日，来那帕韦获得美国FDA批准。来那帕韦被引入海南博鳌乐城距离其在美获批仅8个工作日，实现“全球同步”准入，有望进一步提升我国HIV防控格局的多元化进程。->点击文末阅读原文，解锁完整双语新闻No.3 / 晶泰科技与辉瑞扩大合作，共同开发全新一代的分子模拟平台2025年6月30日，晶泰科技（2228.HK）宣布与全球生物制药巨头辉瑞扩大战略合作，共同开发全新一代的分子模拟平台以驱动新药研发。此次合作旨在进一步融合先进的物理算法的精确度与前沿AI模型的速度和规模化能力，从而全面提升分子模拟平台的效率、精度和所覆盖的化学空间广度，显著加速小分子药物的发现与开发进程。本次合作升级后，双方团队将针对辉瑞专有的化学空间，开发更精准的预测模型，并拓展该平台在小分子药物研发领域的更多应用场景。晶泰科技将为辉瑞本地化部署其自主研发的 XFEP 自由能微扰平台，其中涵盖从参数定制到 FEP 计算的全流程，以全面赋能辉瑞药物研发工作。该平台以实现更高精度、更高通量和更优用户体验为目标，将为辉瑞科学家提供跨场景的药物设计与开发支持。->点击文末阅读原文，解锁完整双语新闻行业政策No.1 / 美国FDA对批准的CAR-T产品取消REMS2025年6月27日，美国FDA宣布，取消针对已获批BCMA和CD19靶向CAR-T细胞疗法的风险评估和缓解策略（REMS）要求。FDA此次取消REMS要求的范围涵盖多款已上市的CAR-T产品，包括百时美施贵宝的Abecma和Breyanzi、吉利德科学的Yescarta和Tecartus、强生与传奇生物的Carvykti以及诺华的Kymriah。值得注意的是，Autolus公司的CD19 CAR-T疗法Aucatzyl在2024年11月获批时就未被要求实施REMS。取消上述产品的REMS移除了医院及其相关诊所分发产品必须经过特别认证并现场即时使用托珠单抗的要求。这些CAR-T细胞免疫疗法的风险信息可以通过目前的产品标签（包括细胞因子释放综合征和神经毒性风险的黑框警告以及药物指南）充分传达。->点击阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ olivia.xu@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

上市批准免疫疗法细胞疗法临床3期

2025-06-30

·佰傲谷BioValley

FDA进一步放宽对CAR-T的安全要求

上周四（2025年6月26日），美国FDA宣布取消对已批准的BCMA和CD19靶向CAR-T的风险评估和缓解策略（REMS）。REMS是一项药物安全计划，以确保某些具有严重安全问题的药物的益处大于其风险。由于CRS和神经毒性，从CAR-T的首次批准到2025年6月，CAR-T治疗一直被限制通过REMS获得。包括Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta已经被取消REMS。而另一款于2024年11月批准的Aucatzyl，在批准之际就无需REMS。取消REMS，是因为不再需要REMS来确保上述的CAR-T治疗的益处大于风险，同时还能最大限度地减少医疗保健系统对于REMS的负担。值得注意的是，取消了REMS后，也取消了分发CAR-T的医疗单位的专门认证和现场立即获得托珠单抗的要求。此外，更新后药品标签将与取消REMS保持一致，简化给药后监测，标签更新包括修改至少2周（包括至少1周每天一次）用药后监测、指导患者在医疗机构附近逗留至少2周（原来为4周）、建议患者给药后2周内避免驾驶（原来为8周）。FDA预计取消REMS和标签更新有助于改善CAR-T药物的可及性，尤其是在美国农村地区。另外，持续监测和评估所有生物制品（包括CAR-T）的安全性仍是FDA的首要任务。所有CAR-T治疗都将继续通过不良事件报告要求进行常规安全监测。取消上述CAR-T产品的REMS并不会改变FDA对制造商进行上市后观察性研究的要求，以评估继发性恶性肿瘤的风险和长期安全性，并在产品给药后对患者进行 15 年的随访。小结该消息发布后，Leerink Partners分析师Daina Graybosch在给投资者的一份报告中写道，安全监控的变化，特别是减少驾驶限制的举措，可能有助于扩大美国细胞疗法市场。同时受该消息的影响，CAR-T销售较好的两家企业传奇生物和吉利德的股价在上周五股价均有所上涨，其他几家供应商股价持平。实际上，这已经不是FDA第一次放宽对CAR-T治疗的安全要求了。去年，FDA逐渐取消了临床医生报告CAR-T严重副作用的报告要求。这些措施都将推动CAR-T治疗的进一步发展，提升其可及性；同时都标志着，CAR-T细胞正在成为一种更标准、更成熟的肿瘤治疗方法。参考资料：1.https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor2.https://endpoints.news/fda-loosens-safety-requirements-for-car-ts-in-move-to-boost-access/········

细胞疗法免疫疗法疫苗

2025-06-27

·Firstwordpharma

FDA eliminates barrier to CAR-T accessibility

The FDA will no longer require healthcare facilities be specially certified to administer currently approved CAR-T cell therapies, a move intended to make the potentially curative cancer treatments more accessible to patients. The change, announced this week, was made because the FDA determined that the risk evaluation and mitigation strategy (REMS) required of CAR-Ts "is no longer necessary to ensure that the benefits… outweigh their risks."In addition to the certification requirement for hospitals and their associated clinics, under the REMS, the facilities also needed to have on-site, immediate access to tocilizumab, a medication used to treat cytokine release syndrome (CRS), a potentially deadly adverse event associated with CAR-Ts. The REMS requirement will be removed from all approved CD19- and CD20-targeting CAR-Ts, including Bristol Myers Squibb's Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), Johnson & Johnson's Carvykti (ciltacabtagene autoleucel), Novartis' Kymriah (tisagenlecleucel), and Gilead's Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).The FDA determined that risks of CAR-Ts could be "conveyed adequately" by the label of each product, which features a boxed warning for CRS and neurological toxicities, as well as medication guides. "Physicians and institutions now have greater experience identifying and managing toxicities with the currently approved CAR-T products," said Richard Pazdur, director of the FDA's Oncology Center of Excellence. "This approach will potentially facilitate patient access to these treatments while continuing to prioritise safety."

细胞疗法免疫疗法

100 项与托珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02596	托珠单抗	L04AC07	DB06273

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
系统性硬化相关的间质性肺病	美国	Genentech, Inc.	2021-03-04
成人斯蒂尔病	日本	Chugai Pharmaceutical Co., Ltd.	2019-05-22
大动脉炎	日本	Chugai Pharmaceutical Co., Ltd.	2017-08-25
新型冠状病毒感染	欧盟	Roche Registration GmbH	2009-01-16
新型冠状病毒感染	冰岛	Roche Registration GmbH	2009-01-16
新型冠状病毒感染	列支敦士登	Roche Registration GmbH	2009-01-16
新型冠状病毒感染	挪威	Roche Registration GmbH	2009-01-16
细胞因子释放综合征	欧盟	Roche Registration GmbH	2009-01-16
细胞因子释放综合征	冰岛	Roche Registration GmbH	2009-01-16
细胞因子释放综合征	列支敦士登	Roche Registration GmbH	2009-01-16
细胞因子释放综合征	挪威	Roche Registration GmbH	2009-01-16
巨细胞动脉炎	欧盟	Roche Registration GmbH	2009-01-16
巨细胞动脉炎	冰岛	Roche Registration GmbH	2009-01-16
巨细胞动脉炎	列支敦士登	Roche Registration GmbH	2009-01-16
巨细胞动脉炎	挪威	Roche Registration GmbH	2009-01-16
幼年特发性关节炎	欧盟	Roche Registration GmbH	2009-01-16
幼年特发性关节炎	冰岛	Roche Registration GmbH	2009-01-16
幼年特发性关节炎	列支敦士登	Roche Registration GmbH	2009-01-16
幼年特发性关节炎	挪威	Roche Registration GmbH	2009-01-16
少关节关节炎	欧盟	Roche Registration GmbH	2009-01-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
低氧性呼吸衰竭	临床3期	美国	Genentech, Inc.	2020-04-20
骨关节炎	临床3期	法国	Hoffmann-La Roche, Inc.	2015-11-20
疼痛	临床3期	法国	Hoffmann-La Roche, Inc.	2015-11-20
炎症	临床3期	丹麦	Hoffmann-La Roche, Inc.	2014-05-28
炎症	临床3期	芬兰	Hoffmann-La Roche, Inc.	2014-05-28
炎症	临床3期	挪威	Hoffmann-La Roche, Inc.	2014-05-28
炎症	临床3期	瑞典	Hoffmann-La Roche, Inc.	2014-05-28
系统性硬皮病	临床3期	美国	Hoffmann-La Roche, Inc.	2012-03-01
系统性硬皮病	临床3期	加拿大	Hoffmann-La Roche, Inc.	2012-03-01
系统性硬皮病	临床3期	法国	Hoffmann-La Roche, Inc.	2012-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04479358 (COVIDOSE-2, CTgov)	临床2期	新型冠状病毒感染	85	Standard of Care (Sub-study A, Tocilizumab-Free Standard of Care)	願築鏇壓憲鑰遞壓糧製(壓鏇獵醖窪膚顧蓋顧蓋) = 壓遞範鏇簾簾蓋構齋範構衊選衊築製醖簾餘醖 (積構獵蓋壓艱鹽鹽繭鏇, 糧選廠簾鏇艱艱網夢糧 ~ 積觸選齋製鹹鏇鹹壓齋) 更多	-	2025-06-05
NCT04479358 (COVIDOSE-2, CTgov)	临床2期	新型冠状病毒感染	85	Tocilizumab (Sub-study A, Tocilizumab 40mg)	願築鏇壓憲鑰遞壓糧製(壓鏇獵醖窪膚顧蓋顧蓋) = 鹽夢觸夢鬱構窪製鬱簾構衊選衊築製醖簾餘醖 (積構獵蓋壓艱鹽鹽繭鏇, 餘構窪範構夢齋餘壓鑰 ~ 鑰壓範膚繭糧蓋衊憲夢) 更多	-	2025-06-05
ASCO2025	N/A	复发性多发性骨髓瘤 BCMA	20	Teclistamab	製簾蓋範襯築鏇餘獵憲(淵顧襯顧範遞觸繭鹹壓) = CRS occurred in 2 subjects (10%), all grade 1 廠範糧淵構網餘觸夢衊 (顧構廠蓋憲淵鑰醖糧淵 ) 更多	积极	2025-05-30
NCT03155347 (CTR20170141, Pubmed \| JAMA Netw Open)	临床3期	类风湿关节炎	340	Tocilizumab-methotrexate	觸範襯顧遞艱餘壓遞觸(築壓鹹獵繭鹹構範膚廠) = 窪艱襯淵顧繭鏇夢範構鏇齋鹹遞糧鏇鹹繭膚製 (襯壓網觸窪繭顧鹽膚醖, 14.7 ~ 41.2)	积极	2025-05-19
NCT03155347 (CTR20170141, Pubmed \| JAMA Netw Open)	临床3期	类风湿关节炎	340	Tocilizumab-placebo	觸範襯顧遞艱餘壓遞觸(築壓鹹獵繭鹹構範膚廠) = 壓淵廠選鹹膚淵網艱艱鏇齋鹹遞糧鏇鹹繭膚製 (襯壓網觸窪繭顧鹽膚醖, 11.7 ~ 38.3)	积极	2025-05-19
ATS2025	N/A	肺炎	-	Tocilizumab	觸憲艱艱廠構廠壓衊鏇(積壓廠鏇鹽艱獵膚淵獵) = 築餘夢選觸鑰積艱觸築鏇衊範糧糧鑰網醖膚艱 (膚鹹餘鬱鹽願製醖衊膚 )	积极	2025-05-16
ATS2025	N/A	肺炎	-	IVIG	觸憲艱艱廠構廠壓衊鏇(積壓廠鏇鹽艱獵膚淵獵) = 淵簾鹽製糧鏇範鹽鑰選鏇衊範糧糧鑰網醖膚艱 (膚鹹餘鬱鹽願製醖衊膚 )	积极	2025-05-16
ATS2025	N/A	新型冠状病毒感染 C-reactive protein (CRP)	-	Tocilizumab	網鹹廠顧壓鑰窪鹽製鹹(遞鹽淵網壓膚夢築觸遞) = 鏇積遞顧製鹹網壓鬱鑰網窪憲簾壓廠餘遞夢衊 (遞顧餘觸構簾範網鏇獵 )	积极	2025-05-16
PS1732 (EHA2025)	N/A	-	10	Teclistamab	窪鏇構壓積選製膚衊鹽(餘繭願簾築製醖範遞顧) = Three patients developed grade 3-4 bacterial infections, leading to discontinuation of treatment in two patients 鏇顧廠簾鑰鏇繭醖廠襯 (鹹糧夢築夢顧鏇蓋膚築 ) 更多	积极	2025-05-14
NCT02735707 (Pubmed \| Thorax)	临床3期	新型冠状病毒感染	2,274	Tocilizumab	鏇觸醖鏇淵餘簾網壓壓(淵壓構簾遞餘夢醖簾膚) = 遞壓蓋製窪醖襯衊窪構鏇衊鏇餘蓋衊獵憲齋鹹 (積網觸遞糧鹽淵憲製選, -1 ~ 16)	积极	2025-05-13
NCT02735707 (Pubmed \| Thorax)	临床3期	新型冠状病毒感染	2,274	Sarilumab	鏇觸醖鏇淵餘簾網壓壓(淵壓構簾遞餘夢醖簾膚) = 齋憲鏇製遞願夢獵餘廠鏇衊鏇餘蓋衊獵憲齋鹹 (積網觸遞糧鹽淵憲製選, -1 ~ 17)	积极	2025-05-13
P12-8.009 (AAN2025)	N/A	视神经脊髓炎 anti-AQP4 antibodies \| anti-MOG	1	Rituximab	廠膚鑰製餘鏇憲繭襯構(蓋窪夢繭鑰鹽鑰膚窪窪) = 窪艱繭鏇艱艱觸襯獵壓積膚遞憲鏇蓋築範襯艱 (範網選鏇餘鏇簾願鏇鑰 )	积极	2025-04-07
NCT03999749 (CTgov)	临床2期	不可切除的黑色素瘤	71	Ipilimumab+Nivolumab+Tocilizumab	願遞夢範鑰範遞網壓齋 = 鹽醖鬱願餘齋醖網觸鑰膚鏇鹹醖範簾鏇糧醖遞 (憲夢壓窪製觸艱艱網廠, 淵蓋襯鏇齋憲築顧壓繭 ~ 壓膚醖淵願鑰蓋簾鬱製) 更多	-	2024-10-09
ESMO2024	N/A	关节炎	-	Tocilizumab 8 mg/kg	築願觸願繭鏇膚廠夢憲(製膚淵壓鬱窪鏇蓋餘網) = 艱製齋糧願積遞膚遞觸夢鏇鏇獵鏇齋齋夢衊顧 (齋鏇觸糧鏇淵繭構鑰鑰 ) 更多	-	2024-09-14